Compare Crispr Therapeutics AG (CRSP) vs Gartner Inc (IT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Gartner Inc — how do they compare? Crispr Therapeutics AG trades at $50.68 (market cap $4.97B), while Gartner Inc trades at $132.89 (market cap $8.90B). The key difference: Gartner Inc is the larger of the two by market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Gartner Inc nearer its low. Which is the better fit depends on your goals.
| CRSP | IT | |
|---|---|---|
Market Cap | $4.97B | $8.90B |
Sector | Health | Technology |
52-Week High | $76.78 | $363.58 |
52-Week Low | $44.34 | $125.68 |
Enterprise Value | $3.32B | $10.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Gartner (IT) trades at $141.31, up 6.06% today, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a 68.99% gross margin and 11.44% net margin, though 2025 net income declined to $729 million. Recent news highlights its leadership in AI platforms, but an ongoing legal investigation poses a near-term risk.
Outlook remains positive with a consensus price target of $157.60, suggesting 11.5% upside. Key opportunities include sustained demand for IT research and consulting, while risks involve heightened competition and the February 2025 legal probe. Institutional sentiment is mixed with 27.8% buy ratings amid cost pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
